Competition is on the horizon for costly narcolepsy treatments
pharmaphorum
DECEMBER 14, 2022
But increased competition is on the horizon. Competition starts to heat up. Harmony Biosciences introduced Wakix to the market in 2019 as the first non-controlled substance for the treatment of narcolepsy. Furthermore, Molina stated Jazz “suppressed generic competition and raised the price of Xyrem 841% between 2007 and 2014.”
Let's personalize your content